MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3501-3508

  Yu, Xiaotang ^a,b   Zhang, Xinchen ^a   Bi, Tie ^c   Ding, Yanfang ^a   Zhao, Jinyao ^a   Wang, Chang ^c   Jia, Tingting ^a   Han, Dan ^a   Guo, Gordon ^d   Wang, Bo ^b   Jiang, Jiyong ^c   Cui, Shiying ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Department of Pathology and Forensic Medicine ^*  (China)

^c Centralab   (China)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

FIGO stage; MicroRNA; MicroRNA 509; MicroRNA 510; Ovarian serous carcinoma; Prognostic predictor

Indexed keywords

MICRORNA; MICRORNA 135A; MICRORNA 148B; MICRORNA 15B; MICRORNA 200A; MICRORNA 202; MICRORNA 296 5P; MICRORNA 345; MICRORNA 372; MICRORNA 375; MICRORNA 376A; MICRORNA 451; MICRORNA 483 5P; MICRORNA 502 5P; MICRORNA 508 3P; MICRORNA 509 3P; MICRORNA 509 5P; MICRORNA 510; MICRORNA 513A 3P; MICRORNA 551B; MICRORNA 589; MICRORNA 7; MICRORNA 9; MICRORNA 923; MICRORNA 942; MICRORNA 96; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MIDDLE AGED; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; THERAPY RESISTANCE; UPREGULATION; YOUNG ADULT;

EID: 84891486879     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0928-3     Document Type: Article

References (30)

1. Semaan AY, Abdallah RT, Mackoul PJ. The role of laparoscopy in the treatment of early ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):121-6.
2. Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecol Oncol. 2011;120(3):393-403.
3. Van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 2010;42(8):1282-90.
4. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2011;585:2087-99.
5. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 2009;15(24):7684-92.
6. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol. 2009;114(2):253-9.
7. Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One. 2010;5(9), e13067.
8. Bentink S, Haibe-Kains B, Risch T, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012;7(2), e30269.
9. Zhang L, Volinia S, Bonome T. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008;105(19):7004-9.
10. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012;5:164.
11. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699-707.
12. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425-33.
13. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273-81.
14. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecol Oncol. 2012;125:655-60.
15. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Patho. 2009;40(9):1213-23.
16. Morin PJ DN. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 2010;17(1):F77-89.
17. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19-36.
18. Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116:117-25.
19. Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol. 2011;122(1):149-54.
20. He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31(28):3357-69.
21. Wang F, Li Y, Zhou J, et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol. 2011;179(5):2580-88.
22. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33-42.
23. Yamashita S, Yamamoto H, Mimori K, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology. 2012;82(4):205-12.
24. Tian RQ, Wang XH, Hou LJ, et al. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem. 2011;286(29):25556-63.
25. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3(1):44-57.
26. Zhai Q, Zhou L, Zhao C. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 2012;419(4):621-6.
27. Millan MJ. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol. 2011;11(1):11-22.
28. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2010;70(1):36-45.
29. Chen W, Tang Z, Sun Y, Zhang Y, Wang X, Shen Z, et al. miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. Exp Ther Med. 2012;3(2):351-6.
30. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol. 2006;60(1):19-37.